Increasing dairy intake can cut falls, fractures for seniors
Oct 21, 2021
An intervention to increase calcium and protein intake using dairy foods was beneficial in a study involving older adults who live in long-term care facilities.
FDA approves first interchangeable biosimilar for inflammatory diseases
Oct 19, 2021
Cyltezo is first interchangeable monoclonal antibody for rheumatoid, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and chronic plaque psoriasis.
FDA panel recommends approval of Johnson & Johnson booster shot
Oct 15, 2021
The booster shot is recommended for anyone 18 years and older, to be given at least two months after the first dose.
Merck to ask FDA for emergency approval of its new antiviral pill for COVID-19
Oct 01, 2021
The new medication is just one of several antiviral pills now being tested in studies.
NIH spending nearly $470 million on ‘long-haul COVID’ study
Sep 16, 2021
The goal is to uncover why some people have prolonged symptoms or develop new or returning symptoms after recovering from COVID-19.
Road traffic, railway noise linked to increased dementia risk
Sep 10, 2021
The general pattern showed higher hazard ratios with higher noise exposure, with levelling off or a decline at higher noise levels.
Which cancer patients need a COVID-19 booster shot most?
Sep 07, 2021
National Comprehensive Cancer Network Vaccination Advisory Committee guidance says several groups should be considered eligible immediately for a third dose of either of the mRNA vaccines.
Half of American workers support COVID-19 vaccination, mask mandates in workplace
Aug 27, 2021
The poll was conducted before the FDA granted full approval to the Pfizer COVID-19 vaccine.
J&J says booster shot ups immune response to COVID-19
Aug 25, 2021
The Johnson & Johnson vaccine was not part of the government’s initial booster plan, announced last week. But the company now hopes to be part of the first round of additional shots, which could...
Pfizer-BioNTech COVID-19 vaccine receives full FDA approval
Aug 23, 2021
The vaccine will now be marketed as Comirnaty and is fully approved for the prevention of COVID-19 in individuals 16 years and older.